Use of nonsteroidal anti-inflammatory drugs and risk of oral cancer: a cohort study by Friis, S et al.
Short Communication
Use of nonsteroidal anti-inflammatory drugs and risk of oral
cancer: a cohort study
S Friis*,1, A Poulsen
1, L Pedersen
2, JA Baron
3 and HT Sørensen
2
1Institute of Cancer Epidemiology, Department of Genetics and Medicine, Danish Cancer Society, DK-2100 Copenhagen, Denmark;
2Department of
Clinical Epidemiology, Aarhus University Hospital, Ole Worms Alle ´ 1150, DK-8000 Aarhus C, Denmark;
3Departments of Medicine and Community and
Family Medicine, Dartmouth Medical School, Dartmouth College, Hanover 03755-3861, NH, USA
Epidemiologic data regarding the chemopreventive potential of nonsteroidal anti-inflammatory drugs (NSAIDs) against oral cancer
are sparse. We found a relative risk for oral cancer of 1.2 (95% CI, 1.0–1.6) among 169589 Danish NSAID users (X2 prescriptions),
with no apparent trends in subgroups. Our study provided no clear evidence that NSAIDs may protect against oral cancer.
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There is substantial experimental and epidemiological evidence
that aspirin and other nonsteroidal anti-inflammatory drugs
(NSAIDs) protect against colorectal adenomas and cancer (Baron,
2003; Ulrich et al, 2006). Epidemiologic studies have also
consistently pointed to inverse associations between NSAID use
and cancers of the stomach and oesophagus, whereas the results
are mixed for other cancer sites (Gonzalez-Perez et al, 2003).
Studies of animal models and human cancer cell lines have
indicated that the potential chemopreventive effect of NSAIDs
might extend to oral cancer (Goodin and Shiff, 2004; Wang, 2005),
and this year a large phase III prevention trial of COX-2 inhibitors
in patients with premalignant oral lesions (leukoplakia) is
scheduled to be launched (Nelson, 2006). Interestingly, only a
few epidemiological studies have provided data on the relationship
between NSAID use and oral cancer, and the data are conflicting
(Thun et al, 1993; Bosetti et al, 2003; Sørensen et al, 2003). This
paucity of epidemiologic data prompted us to examine the
incidence of oral cancer in a large cohort of NSAID users in
Denmark.
MATERIALS AND METHODS
The study was carried out within the population of North Jutland
County, Denmark (population approximately 490000 inhabitants),
during the study period 1 January 1991 to 31 December 2002. From
the files of the Danish Civil Registration System, established in
1968 (Frank, 2000), we identified all individuals in the county who
were 16 years or older during the study period and resident in the
county on 1 January 1991. We then excluded all individuals with a
history of cancer (except nonmelanoma skin cancer) before study
entry (1991 or age 16 years) by linkage to the Danish Cancer
Registry, which has had accurate and almost complete nationwide
ascertainment of cancer cases since 1943 (Storm et al, 1997). The
final study population comprised 442654 individuals.
The Danish National Health Service provides tax-supported
health care for all inhabitants and refunds part of patient
expenditures on a wide range of prescribed drugs, including non-
aspirin NSAIDs. In Denmark, non-aspirin NSAID can be obtained
only by prescription, except for low doses of ibuprofen which
account for approximately 14% of the total use (Sørensen et al,
2003). All health-related services are registered to individual
patients by use of a civil registry number assigned to all Danish
citizens, which encodes gender and date of birth. In North Jutland
County, pharmacy data are transferred to a research prescription
database, which was initiated in 1989 and covered all pharmacies
by 1991 (Gaist et al, 1997). The database holds key information
on all prescriptions for refundable drugs dispensed from
pharmacies in the county, including the type of drug prescribed
according to the ATC classification system (World Health
Organisation, 2001), date of dispensing at the pharmacy, and
the civil registry number. Use of the civil registry number allows
for the establishment of complete prescription histories for each
individual and secures valid linkage between population-based
registers.
Using the files of the prescription database and the cancer
registry, we identified 169589 individuals in the study population
who had redeemed two or more non-aspirin NSAID prescriptions
(ATC codes, M01A) during the study period, and who were free of
cancer at the date of their second prescription. For all individuals
in the study population, we also obtained information on
diagnoses of chronic obstructive pulmonary disease (COPD) from
the County Hospital Discharge Registry, a computerised database
containing information on all non-psychiatric hospital admissions
(since 1977) and outpatient visits (since 1995) in the county
(Skriver et al, 2005).
All individuals in the study population were followed from 1
January 1991 or age 16 years, whichever occurred latest, until
date of primary oral (mouth and tongue) cancer, other primary
cancer (except nonmelanoma skin cancer), death, migration, or 31
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yDecember 2002, whichever occurred first. The person time of the
study subjects was distributed according to use of NSAIDs in
exposed time (X2 prescriptions) (NSAID use) and unexposed
time (no prescriptions) (nonuse). Person time between first and
second NSAID prescription was excluded from the analyses to
reduce the possible association between NSAIDs and oral cancer
due to confounding by indication.
We calculated age- and gender-standardised incidence rates of
oral cancer by applying direct standardisation in gender-specific
5-year age groups to the age distribution in the entire study
population. Age- and gender-standardised incidence rate ratios
(IRR) were computed by dividing incidence rates of oral cancer for
NSAID users with incidence rates for nonusers. We categorised
NSAID use into two groups based on the number of redeemed
prescriptions (2–9 prescriptions, 10þ prescriptions). We further
performed a subanalysis according to a history of COPD (diagnosis
in the Hospital Discharge Registry during the period 1977–2002),
as an indirect control for smoking.
RESULTS
We identified 75 cases of oral cancer among NSAID users during
977627 person-years of follow-up (mean, 5.8 years) and 110 cases
among nonusers during 2521145 years of follow-up. The age-and
gender-standardised incidence rate was 6.1 per 100000 person-
years among NSAID users and 4.9 per 100000 person-years among
nonusers. The table presents the relative risk estimates for oral
cancer according to use of NSAIDs (Table 1). All IRR estimates
were close to one and stratification by number of prescriptions or
history of COPD revealed no apparent trends, although the IRR
estimates for COPD patients tended to be slightly lower than those
for the full cohort. The results did not change materially when
stratified according to gender (data not shown).
DISCUSSION
Our large population-based study based on registers with
essentially complete and unbiased ascertainment of prescriptions,
hospitalisations and outpatient visits for COPD, and cancer
outcomes provided no evidence that NSAID intake prevents oral
cancer. The incidence of oral cancer is increasing in many
countries, and the lack of efficient therapy and the considerable
associated morbidity and mortality make chemoprevention
attractive (Goodin and Shiff, 2004; Wang, 2005), particularly since
this might be targeted to high-risk individuals with leukoplakia or
other precursor lesions (Nelson, 2006). NSAIDs have shown
promise as chemopreventive agents for oral cancer in experimental
studies (Goodin and Shiff, 2004), but the available epidemiologic
data including the present analysis do not support a major
protective effect of NSAIDs against oral cancer.
Our findings may have been influenced by differences in NSAID
use according to important risk factors for oral cancer, notably
smoking and alcohol consumption. We were only able to indirectly
control for smoking by examining risk in a subset of patients
hospitalised with COPD, of whom the large majority can be
assumed to have been smokers. Our inability to adjust for actual
use of tobacco, alcohol consumption, and over-the-counter
purchase of low-dose ibuprofen and aspirin may have obscured
a preventive effect of NSAID use against oral cancer. However,
analyses of US health care utilisation data sets indicate that these
potential confounders have limited influence in studies of NSAID
use and various health outcomes (Schneeweiss et al, 2005). Also,
our finding of no substantial trends in IRRs over number of
NSAID prescriptions argues against a major protective effect of
NSAIDs on the development of oral cancer. The lack
of any clear effect even after stratification by history of COPD
similarly suggests no appreciable confounding by smoking,
although these analyses were based on small numbers. Further
epidemiological studies with large sample sizes and comprehensive
information on potential confounders may be warranted to
evaluate the chemopreventive potential of NSAIDs against oral
cancer.
ACKNOWLEDGEMENTS
The study received financial support from the Western Danish
Research Forum for Health Sciences (Vestdansk Forskningsforum),
Dannins Foundation, and the Danish Cancer Society.
REFERENCES
Baron JA (2003) Epidemiology of non-steroidal anti-inflammatory drugs
and cancer. Prog Exp Tumor Res 37: 1–24
Bosetti C, Talamini R, Franceschi S, Negri E, Garavello W, Vecchia CL
(2003) Aspirin use and cancers of the upper aerodigestive tract. Br J
Cancer 88: 672–674
Frank L (2000) Epidemiology. When an entire country is a cohort. Science
287: 2398–2399
Gaist D, Sørensen HT, Hallas J (1997) The Danish prescription registries.
Dan Med Bull 44: 445–448
Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R (2003) Effects of
non-steroidal anti-inflammatory drugs on cancer sites other than the
colon and rectum: a meta-analysis. BMC Cancer 3: 28
Goodin S, Shiff SJ (2004) NSAIDs for the chemoprevention of oral
cancer: promise or pessimism? Commentary re: J. L. Mulshine et al.
Randomized, double-blind, placebo-controlled, phase IIB trial of the
cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal
leukoplakia. Clin Cancer Res 10:1565–1573, 2004. Clin Cancer Res 10:
1561–1564
Table 1 Age- and gender-standardised rate ratios for oral cancer among






No prescriptions 110 2521145 Reference
2+ prescriptions 75 977627 1.2 (1.0–1.6)
2–9 prescriptions 17 192241 1.0 (0.6–1.6)
10+ prescriptions 58 785386 1.3 (1.0–1.6)
No chronic obstructive pulmonary disease*
No prescriptions 102 2436925 Reference
2+ prescriptions 66 919129 1.2 (0.9–1.5)
2–9 prescriptions 13 174921 0.9 (0.5–1.6)
10+ prescriptions 53 744208 1.3 (1.0–1.7)
Chronic obstructive pulmonary disease
No prescriptions 8 84220 Reference
2+ prescriptions 9 58499 0.9 (0.4–1.7)
2–9 prescriptions 4 17320 1.2 (0.3–3.1)
10+ prescriptions 5 41179 0.8 (0.2–1.8)
*No hospitalisation for chronic obstructive pulmonary disease.
NSAID and oral cancer
S Friis et al
364












yNelson NJ (2006) Years of research come to fruition with launch of oral
cancer prevention trial. J Natl Cancer Inst 98: 88–89
Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH (2005) Adjusting
for unmeasured confounders in pharmacoepidemiologic claims data
using external information: the example of COX2 inhibitors and
myocardial infarction. Epidemiology 16: 17–24
Skriver MV, Nørgaard M, Poulsen AH, Friis S, Harving H, Fryzek
J, McLaughlin JK, Blot WJ, Olsen JH, Sørensen HT (2005) Use
of nonaspirin NSAIDs and risk of lung cancer. Int J Cancer 117:
873–876
Sørensen HT, Friis S, Nørgard B, Mellemkjær L, Blot WJ, McLaughlin
JK, Ekbom A, Baron JA (2003) Risk of cancer in a large cohort of
nonaspirin NSAID users: a population-based study. Br J Cancer 88:
1687–1692
Storm HH, Michelsen EV, Clemmensen IH, Pihl J (1997) The Danish Cancer
Registry – history, content, quality and use. Dan Med Bull 44: 535–539
Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath Jr CW (1993)
Aspirin use and risk of fatal cancer. Cancer Res 53: 1322–1327
Ulrich CM, Bigler J, Potter JD (2006) Non-steroidal anti-inflammatory
drugs for cancer prevention: promise, perils and pharmacogenetics.
Nat Rev Cancer 6: 130–140
Wang Z (2005) The role of COX-2 in oral cancer development, and
chemoprevention/treatment of oral cancer by selective COX-2 inhibitors.
Curr Pharm Des 11: 1771–1777
World Health Organization Collaborating Centre for Drug Statistics
Methodology (2001) Guidelines for ATC Classification and DDD Assign-
ments. World Health Organization Collaborating Centre for Drug
Statistics Methodology: Oslo
NSAID and oral cancer
S Friis et al
365
British Journal of Cancer (2006) 95(3), 363–365 & 2006 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
y